• 1
    Boivin JF, Hutchison GB, Zauber AG et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87: 73241.
  • 2
    van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 48797.
  • 3
    Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 21018.
  • 4
    Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 174960.
  • 5
    Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 312835.
  • 6
    Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495502.
  • 7
    Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 34839.
  • 8
    Rueda Domínguez A, Márquez A, Gumá J et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004; 15: 1798804.
  • 9
    Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 47581.
  • 10
    Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 529.
  • 11
    Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 2007; 25: 374652.
  • 12
    Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 2628.
  • 13
    Munker R, Glass J, Griffeth LK et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004; 15: 1699704.
  • 14
    Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 205.
  • 15
    Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 11608.
  • 16
    Song MK, Chung JS, Shin HJ et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012; 91: 697703.
  • 17
    Song MK, Chung JS, Shin HJ et al. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci 2012; 103: 47782.
  • 18
    Song MK, Chung JS, Shin HJ et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Leuk Res 2013; 37: 5863.
  • 19
    Oh MY, Chung JS, Song MK et al. Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol 2013; 97: 397402.
  • 20
    Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma. J Clin Oncol 2003; 19: 36018.
  • 21
    Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol 1989; 7: 16306.
  • 22
    Freudenberg LS, Antoch G, Schütt P et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 3259.
  • 23
    Boellaard R, O'Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181200.
  • 24
    Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl 2005; 66: 13540.
  • 25
    Hoppe RT, Advani RH, Ai WZ et al. National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 58997.
  • 26
    DeVita VT Jr. Hodgkin's disease-clinical trials and travails. N Engl J Med 2003; 348: 23756.
  • 27
    Longo DL. Radiation therapy in the treatment of Hodgkin's disease–do you see what I see? J Natl Cancer Inst 2003; 95: 9289.
  • 28
    Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005; 97: 13945.
  • 29
    Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005; 23: 45746.
  • 30
    Gobbi PG, Ghirardelli ML, Solcia M et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001; 19: 138894.
  • 31
    Gobbi PG, Broglia C, Di Giulio G et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101: 182434.
  • 32
    Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 42933.
  • 33
    Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 1320.
  • 34
    Stumpe KD, Urbinelli M, Steinert HC et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 7218.
  • 35
    Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007; 21: 84154.